Dr. William C. Maier is Scientific Officer for Epidemiology at Mapi Research Trust.
Dr. Maier has over 20 years of experience in drug development and commercialization at pharmaceutical companies in Europe and the United States. Dr. Maier has most recently served as Vice President and Head of Epidemiology for REGISTRAT-Mapi. He was previously Senior Director of Epidemiology at GlaxoSmithKline and Elan Pharmaceuticals and led research groups conducting observational research to support reimbursement, marketing and drug safety investigations of pharmaceuticals throughout the world. He has worked on over 50 observational studies in several disease areas including respiratory, neurology, psychiatry, autoimmune, cancer, endocrinology, cardiovascular, cerebrovascular, urology, opioid dependency and vaccines.
He routinely provides training seminars to pharmaceutical, biotechnology and medical products companies in Europe and the US on the use and development of real-life data for use in health technology assessment, drug safety and risk management.
In July 2007 he presented the Tysabri Risk Management Plan at an FDA advisory committee meeting.
Dr. Maier is editor of the quarterly PharmacoEpi and Risk Management Newsletter
, which publishes articles on applications of methods, development of new tools and reflections on regulatory developments in product safety, pharmacoepidemiology and risk management.
He is also involved with the International Society of Pharmacoeconomics Research (ISPOR) project to develop a global database of real-life healthcare information (www.ispor.org/DigestOfIntDB/CountryList.aspx
) and is a member of the EMA's European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (www.encepp.eu
). In addition, he is a frequent speaker at medical conferences and has academic appointments in the UK (Dundee) and the USA (North Carolina).